Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.

Date publication

mai 2015

Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Lopez A, Ford AC, Colombel JF, Reinisch W, Sandborn WJ, Peyrin-Biroulet L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25661014

Résumé

The potential for disease modification of tumour necrosis factor antagonists in ulcerative colitis remains debated.

Mots clés

Adalimumab, therapeutic use, Anti-Inflammatory Agents, administration & dosage, Clinical Trials as Topic, Colectomy, statistics & numerical data, Colitis, Ulcerative, drug therapy, Hospitalization, statistics & numerical data, Humans, Infliximab, therapeutic use, Intestinal Mucosa, drug effects, Placebos, administration & dosage, Remission Induction, Tumor Necrosis Factor-alpha, antagonists & inhibitors

Référence

Dig Liver Dis. 2015 May;47(5):356-64